The vitamin D related pathway has been evaluated in carcinogenesis but its genetic contribution remains poorly understood. We examined single-nucleotide polymorphisms (SNPs) in the vitamin D related pathway genes using data from a genome-wide association study (GWAS) of breast cancer in the African Diaspora that included 3,686 participants (1,657 cases). Pathwayand gene-level analyses were conducted using the adaptive rank truncated product test. Odds ratios (OR) and 95% confidence intervals (CI) were estimated at SNP-level. After stringent Bonferroni corrections, we observed no significant association between variants in the vitamin D pathway and breast cancer risk at the pathway-, gene-, or SNP-level. In addition, no association was found for either the reported signals from GWASs of vitamin D related traits, or the SNPs within vitamin D receptor (VDR) binding regions. Furthermore, a decrease in genetically predicted 25(OH)D levels by Mendelian randomization was not associated with breast cancer (p 5 0.23). However, an association for breast cancer with the pigment synthesis/metabolism pathway almost approached significance (pathway-level p 5 0.08), driven primarily by a nonsense SNP rs41302073 in TYRP1, with an OR of 1.54 (95% CI 5 1.24-1.91, p adj 5 0.007). In conclusion, we found no evidence to support an association between vitamin D status and breast cancer risk in women of African ancestry, suggesting that vitamin D is unlikely to have significant effect on breast carcinogenesis. Interestingly, TYRP1 might be related to breast cancer through a non-vitamin D relevant mechanism but further studies are needed.
Establishing a causal relationship between vitamin D status and breast cancer susceptibility is challenging because risk factors associated with incident breast cancer are often also linked to vitamin D deficiency. For example, the association between 25-hydroxyvitamin D concentration [25(OH)D]) and breast cancer observed in previous studies might result from 25(OH)D being a marker of healthier lifestyle (e.g., physical activity and spending time outdoors). 9, 10 However, evidence that genetic factors in the vitamin D related pathway affect breast cancer risk may be used to counter such concerns and support a causal link. 10 Using a candidate gene approach, findings on the relationship between genetic variants in vitamin D related genes and breast cancer risk were also inconsistent. [11] [12] [13] [14] As a limitation, these studies focused mainly on a small set of genes, such as the vitamin D receptor (VDR), group-specific componet (GC), and cytochrome P450 family 24 subfamily A member 1 (CYP24A1). [15] [16] [17] In addition, it is well known that allele frequencies and linkage disequilibrium (LD) pattern are substantially different between individuals of African and European descent. 16 Most of the previous studies were based on populations of European ancestry (EA), [11] [12] [13] 18 and those few which focused on women of African ancestry had inconclusive results. [15] [16] [17] 19 Furthermore, it is now widely accepted that it could be more powerful to explore the association at the pathway-level, 20 considering that the effects of each gene may be small and gene-gene interactions may be important. 21, 22 To date, only the African American Breast Cancer Epidemiology and Risk (AMBER) consortium has applied the pathway approach to test the association between variants in the vitamin D related pathway and breast cancer risk, but it found no statistical significance. 23 Moreover, other studies examined the link between genetic variants and expression levels of two main forms of vitamin D: primary transferred form 25(OH)D and primary active form 1, 25-dihydroxyvitamin D [1, 25(OH) 2 D] . A few genome-wide association studies (GWAS) in Caucasians have reported that 12 single-nucleotide polymorphisms (SNPs) were significantly associated with 25(OH)D levels, [24] [25] [26] [27] which offers an opportunity to ascertain whether 25(OH)D is etiologically involved in breast carcinogenesis by the Mendelian randomization (MR) method using genetic data. 28 On the other hand, the activation of VDR, acting as the binding site of 1,25(OH)2 D, could regulate the expression of multiple target genes, some of which have anti-tumor properties. 29 Thousands of VDR peak locations have also been discovered in different cell lines using chromatin immunoprecipitation sequencing (ChIP-seq). 30 To date, no study has adopted a MR design to estimate the effect of genetically predicted 25(OH)D levels on breast cancer susceptibility, or explored the contributions of genetic variations in ChIP-seq peak regions to breast cancer risk.
Here we resorted to three complementary strategies including MR, pathway and ChIP-seq peak region analyses, to further investigate the role of genetic variants in vitamin D related genes in breast carcinogenesis among women of African descent, an understudied population. We conducted an MR analysis based on known GWAS index SNPs for 25(OH)D levels to estimate the effect of genetically determined lower 25(OH)D levels on breast cancer. We next explored the associations between the entire vitamin D related pathway and breast cancer risk, and tested the correlations between the SNPs within VDR peak locations and breast cancer susceptibility. These analyses will provide an overall picture of vitamin D status and breast cancer risk in women of African ancestry.
Materials and Methods

Study participants
The study populations of the Root consortium have been described previously. 31 Briefly, 3,686 participants of African ancestry from the USA (854 cases and 1,176 controls), Barbados (92 cases and 229 controls) and Nigeria (711 cases and 624 controls) were included. The mean ages of cases and controls were 49.3 and 48.4 years, respectively.
GWAS SNP genotyping and imputation
Information about GWAS genotyping, quality control, imputation and principal component analysis (PCA) analysis has been previously published. 31 Briefly, genotyping was conducted with the Illumina HumanOmni2.5-8v1 array, including about 2.4 million genetic variants. Genotype imputation was done using IMPUTE2 software with the 1000 Genomes Project phase 1 integrated variant as the reference panel. 32 23 ,098,723 SNPs were imputed and included in the GWAS analyses. In this study, to be conservative, 33 we excluded SNPs with an imputation information score < 0.7. To account for population structure, the first ten principal components were computed with the smartpca program in the EIGENSOFT package. VITAMIN_D_RECEPTOR_BINDING"), 35 and the previous AMBER study (vitamin D metabolism and signaling). 23 For each candidate gene, its start and end chromosomal positions plus 10 kb upstream and 10 kb downstream were determined with the UCSC Genome Browser (https://genome.ucsc.edu). SNPs within each gene region were extracted from The Root Consortium GWAS data and defined as "total number of SNPs". Then 12,646 variants were ultimately included (Table  1) . For direct comparison, we also created the same gene lists for the vitamin D metabolism and signaling pathway (11 genes), pigment synthesis and metabolism (29 genes) pathway, and response to UV exposure (23 genes) pathway generated by AMBER (Supporting Information Table 1) . 23 In addition, we examined 14 SNPs linked to vitamin D related traits at p values < 5 3 10
28 from the GWAS Catalog (https://www.ebi.ac.uk/gwas/search?query5vitamin%20d). Consistent with a recently published study, 36 we used four 25(OH)D related SNPs (rs2282679, rs10741657, rs12785878 and rs6013897) as instrument in our MR analysis, and kept the reported effect of each SNP on 25(OH)D level. All SNPs were identified from the Study of Underlying Genetic Determinants of Vitamin D and Highly Related Traits (SUN-LIGHT) Consortium, the largest GWAS (n 5 33,995) published to date for 25(OH)D levels. 24 Moreover, considering that vitamin D signaling occurs mainly through binding 1,25(OH)2 D to VDR, 29 we hypothesized that the genetic variants in the VDR binding regions might affect the VDR-mediated signaling. Across 23,409 previously identified VDR binding sites (ChIP-seq peak locations), 30 we identified 28,638 independent single-nucleotide polymorphisms (SNPs) from our GWAS after pruning with PLINK1.9 (LD r 2 < 0.1).
Statistical analysis
We examined the associations between SNPs and breast cancer risk at pathway-, gene-and SNP-levels. As an exploratory analysis, we also tested whether SNPs are associated with ERor ER1 breast cancer.
The pathway-and gene-level analyses were conducted using the adaptive rank truncated product (ARTP) test with the R package ARTP2. 21, 22 It was chosen for the strength in optimizing the number of SNP P values combined in each gene-level test. 37 To avoid capturing only a few signals due to correlations between the SNPs of significant associations, only 5,542 effective SNPs were selected from 33 genes in the analysis for vitamin D metabolism and signaling pathway. "Effective number of SNPs" means the remaining SNPs after excluding SNPs with minor allele frequency (MAF) < 0.01 and SNPs with lower MAF in every pair of SNPs with correlation r 2 0.8. Statistical significance at gene-level was adjusted by the number of genes examined with Bonferroni correction (0.05/33 5 0.0015). In direct comparison to AMBER study, the adjusted significance thresholds were 0.0045 (0.05/11), 0.0022 (0.05/23), and 0.0017 (0.05/29) for the vitamin D metabolism and signaling pathway, response to UV exposure pathway, and pigment synthesis and metabolism pathway, respectively.
In the single SNP association tests, we used logistic regression with case status as outcome, and an additive model for genotype, adjusting for age (10-year groups), study site and the first four eigenvectors from PCA, using SNPtest. 38 Odds ratio (OR) and 95% confidence interval (CI) was estimated for each SNP. At SNP-level, Bonferroniadjusted p values (p adj ) were calculated by multiplying the original p values by the effective number of independent SNPs. 39 Values of p adj above 1 was capped as 1. We also conducted power calculations for significant SNPs, with a as 0.05 divided by the number of effective SNPs within each gene. Additional power calculations for MR analysis were calculated based on an online sample size calculator (http://www.sample-size.net).
Association signal visualization and SNP functional annotation
Single marker associations for TYRP1 were plotted with LD data using the LocusZoom. 40 Functionality of the most significant SNP and its tag SNPs was explored in HaploReg v4, in which epigenomic data from the ENCODE (Encyclopedia of DNA Elements), the GTEx pilot and RegulomeDB databases were included. 41 Expression quantitative trait loci (eQTL) information in breast tissues were sought in GTEx portal and eQTL Browser (http://eqtl.uchicago.edu/cgi-bin/gbrowse/eqtl/).
RESULTS
The vitamin D metabolism and signaling pathway was not associated with breast cancer risk overall or stratified by ER status (P > 0.5, Table 1 ). At the gene-level, only CYP24A1 was nominally significant associated with ER1 breast cancer (P 5 0.04), but turned to be non-significant after multiple testing correction. The smallest p values for overall breast cancer risk among selected SNPs was 0.0003 but became non-significant with P adj > 0.2 (Supporting Information Table 2 , Supporting Information Fig. 1 ). We found no SNPs with MAF 0.01 within VDR ChIP-seq peak locations to be significantly associated with breast cancer risk after multiple corrections (Supporting Information Table 3 , Supporting Information Fig. 2) .
As a comparative analysis to the AMBER study, the vitamin D metabolism and signaling pathway (11 genes) and the response to UV exposure pathway (23 genes) were not associated with breast cancer risk (all p > 0.16, Supporting Information Table 1 ). However, the pigment synthesis and metabolism pathway (29 genes) seems to be marginally significantly associated with overall (p 5 0.08) and ER-breast cancer risk (p 5 0.07). These associations were driven primarily by a nonsense (stop gained) SNP rs41302073 in TYRP1, with OR for its G allele as 1.54 (95% CI Table 4 ). rs41302073 and its LDlinked SNP (rs116196234) were located in regions with some regulatory elements (Fig. 1, Supporting Information Table 5 ). We did not find any additional eQTL information for both SNPs to further corroborate their association with gene expression and breast cancer (data not shown).
One SNP (rs2060793) linked to 25(OH)D levels was associated with breast cancer risk in our study (p 5 0.032, Table 2), 
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but it was no longer significant after correction for multiple testing. In MR analysis, we found no evidence of LD between any of the four SNPs in populations of African ancestry through LDlink (all pairwise r 2 < 0.01). A decrease in predicted 25(OH)D levels by one standard deviation (SD) on the natural log scale (1 SD 5 1) was not associated with breast cancer (OR 5 1.04, 95% CI: 0.97-1.11, p 5 0.23). Given this null result, we undertook a power calculation. Our sample has an 80% power to exclude effects as small as an OR of 1.10 with alpha as 0.05.
DISCUSSION
In the present study, we found no evidence that genetically determined reduction in 25(OH)D levels conferred an increased risk of breast cancer in the MR analysis. In addition, the susceptibility of breast cancer was not significantly associated with either the reported GWAS signals for vitamin D related traits, or the SNPs within VDR ChIP-seq peak regions. Furthermore, we did not observe any significant association between the vitamin D metabolism and signaling pathway and breast cancer risk among women of African ancestry, at pathway-, gene-, or SNPs level after stringent Bonferroni corrections. However, an association between breast cancer susceptibility and the pigment synthesis and metabolism pathway almost approached significance, driven primarily by a locus from the TYRP1 gene.
Our results confirmed the null association between breast cancer risk and vitamin D metabolism and signaling pathway reported by AMBER. 23 None of the SNPs in this pathway were significantly associated with breast cancer risk in our study. Consistent with AMBER, 42 we did not observe association for The 25-hydroxyvitamin D concentrations will decrease by the beta coefficient value, for every additional one risk allele. Confidence interval information of effect size was not reported. 7 The serum vitamin D-binding protein levels will decrease by the beta coefficient value, for every additional one risk allele.
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previous reported GWAS signals linked to vitamin D related traits in our samples either. In order to understand the uncertain association, we also employed MR to construct a predicted genetically determined reduction in 25(OH)D levels. But it still provided no support for a relationship between predicted 25(OH)D levels and breast cancer susceptibility. Our sample size has at least 80% power to detect an OR of 1.10 per SD change in log predicted 25(OH)D levels. Unlike seasonally varying 25(OH)D levels, genetic variants above mentioned are invariable, thereby it ruled out the possibility of reverse causation concerns. 10 In addition, none of the SNPs within VDR ChIP-seq peak regions were associated with breast cancer. Taken together, studies to date including ours do not support a role for vitamin D on breast cancer susceptibility in women of African ancestry, which harmonizes with the existing guideline. 43 Interestingly, we found that the pigment synthesis and metabolism pathway has a correlation with the development of breast cancer (overall and ER-) with a suggestive trend toward significance. We found a low frequency variant rs41302073 in the TYRP1 gene remains significantly associated with a 54% increased risk of overall breast cancer risk after Bonferroni correction. The AMBER study did not find this association with a larger sample of African Americans, 23 and one possible reason might be that the risk allele of this SNP has a higher MAF and a relatively larger effect in Nigerian women than in African American women. Given that rs41302073 and its tagged SNP rs116196234 in TYRP1 are both monomorphic in Caucasian populations, we could not replicate this finding directly. However, another SNP, rs2762460, in the same gene was nominal significantly associated with overall breast cancer risk (OR 5 0.97, 95% CI: 0.93-0.99, P 5 0.049), based on publicly available data from GAME-ON GWAS (http://gameon.dfci.harvard.edu). TYRP1, encoding tyrosinase-related protein 1, directly regulates the melanin synthesis. 44 TYRP1 was expressed at levels more than two-fold higher in fibroadenomas than in normal tissues, 45 and it was reported to be associated with 25(OH)D concentration. 44 A more likely explanation for its association with breast cancer might be due to its cluster-site response elements that have been shown experimentally to confer transcriptional regulation by p53. 46 In epidemiology studies, the association of TYRP1 with nevi and melanoma has been reported, 47, 48 and two studies also proposed that nevi (melanoma) and breast cancer may share genetic factors. 49, 50 Therefore, TYRP1 could be a candidate gene for different diseases through different mechanisms that require further studies to reveal.
To our knowledge, this is the first study that combined three complementary approaches (pathway, MR and candidate region analyses) to explore the correlation of genetic variants in vitamin D related genes with breast cancer risk among a sizeable number of women of African descent. However, several limitations should be noted. First, despite having >3,600 participants, the present study had limited power to detect individual SNP associations of small magnitude, especially for SNPs with low allele frequency in subtype analyses. Nevertheless, it is already one of the largest studies to date on the genetics of breast cancer in women of African ancestry, and thus raises a realistic demand to conduct more large-scale studies in African populations. Second, we did not find either the associations between SNPs previously linked to vitamin D related traits and breast cancer, or the relationship between predicted 25(OH)D levels and breast cancer based on MR. One possibility could be that these SNPs might have no association with 25(OH)D concentration in our samples, although this measurement is not available. We also acknowledge that all these SNP associations were observed in Caucasians, and may differ in women of African ancestry. Third, we could not find the associations between SNPs in the VDR ChIP-seq peaks and breast cancer risk. Since the existing data was originated from non-breast cancer cell lines, 30 future VDR ChIP-seq studies in breast cancer cells may be more specific and useful. Lastly, our findings require validation, as the gene-level association was not significant after correction for multiple tests. Nonetheless, the identified associations may provide a new clue for future experimental studies to characterize the functional impact of these genetic variations.
In conclusion, in this systematic assessment of genetic variation in the vitamin D related pathway, we found no evidence to support the association between vitamin D status and breast cancer risk in women of African ancestry, suggesting that vitamin D might be unlikely to have clinical significant effect on breast carcinogenesis.
Interestingly, TYRP1 within the pigment synthesis and metabolism pathway, might play a role in breast cancer etiology through non-vitamin D relevant mechanism, which warrants future studies. With the current situation that the findings have been identified in predominately European-ancestry populations, our study added not merely complementary but also comparable results to the association between vitamin D status and breast cancer risk, arousing attention and further study in nonEuropean-ancestry populations.
